Tags: Neuroprotection

announcements

$1.8 Million in New Funding Supports Clinical Stage Treatments

The ADDF announces nearly $1.8 million in new funding, which reflects our commitment to advancing drugs in or near human clinical trials.

blog

Top Five Alzheimer’s Advances in 2017

Our top five advances in 2017 spotlight the substantial progress we have made toward conquering Alzheimer’s and other neurodegenerative diseases.

blog

Closing in on a Cure: Dr. Roberta Diaz Brinton and Allopregnanolone

With funding from the ADDF since 2004, Dr. Roberta Diaz Brinton has developed what may become the first ever regenerative treatment for Alzheimer's disease.

announcements

18th Annual Conference on Alzheimer's Drug Discovery Showcases Non-Amyloid Research

Nearly 200 academic and industry researchers came together to share updates on innovative preclinical and clinical-stage Alzheimer’s disease research at the 18th Annual Conference on Alzheimer's Drug Discovery.

announcements

ADDF Funding Advances M3 Biotechnology Toward Clinical Trials

Our new investment in M3 Biotechnology is advancing its drug program toward clinical trials

announcements

$4 Million in New Grants Support Several First-in-Class Dementia Treatments

We recently awarded eight new grants totaling over $4 million to advance treatments for Alzheimer’s and related dementias. Several of the awards support new approaches to treating these diseases.

blog

Closing in on a Cure: Dr. Michela Gallagher and AGB101

Dr. Michela Gallagher of Agenebio is developing AGB101, which can potentially prevent mild cognitive impairment from progressing to Alzheimer's disease.

announcements

$2.5 Million in New Grants Advance Clinical Trials of Alzheimer’s Treatments

We awarded three new grants in November and December, totaling nearly $2.5 million. The grants represent our commitment to advancing the most promising drugs to clinical trials, the final stages of drug development.  

blog

Closing in on a Cure: Dr. Frank Longo and C-31

We have supported over 20% of all Alzheimer's treatments currently in clinical trials. One of the most promising is C-31, developed by Frank Longo, MD, PhD.

announcements

$1.5 Million in New Grant Funding for Promising Treatments

The Alzheimer’s Drug Discovery Foundation awarded three new grants in September and October totaling nearly $1.5 million.